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Abstract
Background: A mobile health unit may be useful to follow up adult and pediatric patients on antiretroviral
treatment and living in remote areas devoid of laboratory facilities. The study evaluated the use of the simplified,
robust, single-plateform, volumetric, pan-leucogating Auto40 flow cytometer (Apogee Flow Systems Ltd, Hemel
Hempstead, UK) for CD4 T cell numeration in a mobile unit, compared against a reference flow cytometry method.
Methods: The therapeutic mobile unit of the Laboratoire National de Santé Hygiène Mobile, Yaoundé, Cameroon,
was equipped with the Auto40. A FACSCalibur flow cytometer (Becton Dickinson Immuno-cytometry System, San
Jose, CA, USA) was used as reference method. EDTA-blood samples from volunteers were first subjected to CD4 T
cell count in the mobile unit, and an aliquot was sent within 4 hours to Centre International de Référence Chantal
Biya, Yaoundé, for FACSCalibur assay.
Results: Two HIV screening campaigns with the mobile unit were organised in December 2009 and January 2010.
The campaign in the suburb of Yaoundé which was 20 km from the reference laboratory included 188 volunteers
comprising 93 children less than 5 years old. The campaign in Ambang Bikok (53 km far from Yaoundé) included
69 adult volunteers. In Yaoundé suburb, mean ± standard deviation (SD) CD4 T cell count was 996 ± 874 cells/μl
by Auto40, and 989 ± 883 cells/μl by FACSCalibur; in Ambang Bikok, mean ± SD CD4 T cell count was 1041 ± 317
cells/μl by Auto40, and 1032 ± 294 cells/μl by FACSCalibur. Results by Auto40 and FACSCalibur were highly
correlated in Yaoundé (r
2 = 0.982) as in Ambang Bikok (r
2 = 0.921). Bland-Altman analysis showed a close
agreement between Auto40 and FACSCalibur results expressed in absolute count as in percentage in Yaoundé and
Ambang Bikok. When pooling the 257 CD4 T cell count measurements, the Auto40 yielded a mean difference of
+7.6 CD4 T cells/μl higher than by reference flow cytometry; and the sensitivity and specificity of Auto40 in
enumerating absolute CD4 T cell counts of less than 200 cells/μl were 87% and 99%, respectively, and in
enumerating absolute CD4 T cell counts of less than 350 cells/μl were 87% and 98%, respectively. The intrarun and
interun precisions of the Auto40 assay assessed in the mobile unit were 5.5% and 7.9%, respectively.
Conclusions: The Auto40 flow cytometer installed in a therapeutic mobile unit and operated far from its reference
laboratory gave a perfect correlation with the reference method, and could be useful in carrying out
immunological monitoring of HIV-infected patients living in areas without access to laboratory facilities.
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The 2010-revised guidelines of the World Health Orga-
nization (WHO) for scaling up of antiretroviral treat-
ment (ART) in adults and children living in resource-
limited settings [1,2], emphasizes the need of laboratory
monitoring, based first on immunological assessment by
the numeration of CD4 T lymphocytes, mainly to start
ART and monitor patients on ART, and secondly on
HIV-1 RNA load in order to monitor treatment efficacy,
early therapeutic failure and subsequent therapeutic
switch [3-6]. Affordable CD4 T cell counting has gradu-
ally become possible by using simple, compact and
robust low-cost new generation cytometers operating as
single-platform volumetric instruments without the use
of expensive micro beads [7-11].
The scaling up of public ART programs globally has
led to an increased demand for CD4 T cell count tests
[12], especially to assess treatment eligibility. CD4 T cell
count has become the most decentralized and univer-
sally available biological marker to monitor HIV disease
and ART [3]. However, access to CD4 T cell measure-
ment remains a bottleneck to ART scale-up and decen-
tralization, especially in remote rural areas frequently
lacking laboratory infrastructure [13,14].
In order to increase the number of individuals tested
for HIV, in keeping with our target of universal access,
we recently developed a strategy based on bringing the
healthcare package much closer to the people, through
mobile HIV testing units [15], conceived to bring educa-
tion and testing services to hard-to-reach population
[16]. This pilot study, the first in the Central African
region, clearly demonstrated the acceptability, feasibility
and effectiveness of using mobile units as a tool for
mass HIV testing in individuals with limited access to
voluntary counseling and testing [15]. Successful HIV
testing with mobile units was unexpected, given that
resistance and sociocultural impediments to HIV testing
have been identified in Central Africa [17]. In addition,
previous successful experiences in South Africa [18] and
Kenya [19] showed that mobile services for HIV screen-
ing are accessed by different target population compared
with facility-based services, including younger people,
and higher proportion of persons with newly diagnosed
HIV infection.
HIV counseling and screening mobile units may be
complemented with antiretroviral drugs and laboratory
facilities to become ambulatory health units for ART
and follow up adult and pediatric patients living in
remote areas devoid of laboratory facilities. The recently
developed Auto40 flow cytometer (Apogee Flow Systems
Ltd, Hemel Hempstead, UK; http://www.ApogeeFlow.
com) was originally developed for military applications
[10]. It has been adapted for CD4 T cells measurement
within 30 minutes, using a pan-leucogating protocol
with anti-CD4 and anti-CD45 thermo-stable monoclonal
antibodies. Due to the stability of its optical bench, the
Auto40 has been conceived for use on mobile or periph-
eral stationary flow cytometry unit [10]. Finally, the aim
of the present study was to evaluate the usefulness of
the simplified Auto40 flow cytometry system for CD4 T
cell numeration in mobile health unit, according to a
reference flow cytometry method.
Materials and methods
Volunteers, blood sampling and processing
In December 2009 and in January 2010, two HIV
screening campaigns with mobile units were organized
in the outskirts of Yaoundé, the capital city of Camer-
oon, 20 km away from the Laboratoire National de
Santé Hygiène Mobile (LNSHM), the reference labora-
tory for HIV screening mobile campaign in Cameroon
[15], and in Ambang Bikok, a rural setting located 53
km from Yaoundé. In a suburb of Yaoundé, children fol-
lowed up at the Nkoldongo Medical Health District
were also included for CD4 T cell measurement, as part
of an agreement with the Chantal Biya International
Reference Centre for Research and Prevention of HIV/
AIDS (CIRCB), Yaoundé, for free HIV biological moni-
toring. Volunteers had access to primary health care
centers and antenatal clinics, but modern laboratory
facilities were not routinely available.
An aliquot of K3-EDTA-blood sample obtained by
venipuncture in Vacutainer tubes (Becton Dickinson,
Franklin Lakes, NJ, USA), kept at ambient temperature,
was obtained after informed consent from each volun-
teer, patient or child guardian. Each aliquot was first
subjected to CD4 T cell count in the therapeutic mobile
unit, and a second aliquot was send within 4 hours at
CIRCB for measurement by flow cytometry reference
analyzer in the same day of sampling. All blood samples
were unlinked to identifiers.
CD4 T cell measurements
CD4 T cell counting was performed on 2 different flow
cytometers: (1) the FACSCalibur [Becton Dickinson
Immuno-cytometry System (BDIS), San Jose, CA, USA],
a dedicated clinical instrument for CD4 T cell counting
installed at the CIRCB, used as reference method, and
(2) the Auto40 flow cytometer (Apogee Flow Systems
Ltd) equipped with a green laser at 532 nm, a side scat-
ter detector, two fluorescence channels and means for
direct volumetric counting, without requiring a step of
red blood cell lysis. The Auto40 flow cytometer has
been installed in the therapeutic mobile unit of the
LNSHM, using the battery of the van as the source of
electrical energy. An optional sheath fluid recycling cas-
sette reduces sheath fluid consumption and may be of
interest in remote areas where the supply is limited.
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for CD4 T cell counting in the study, as a single-plat-
form flow cytometry technique. Absolute CD4 T cell
counting was performed according to the instructions
provided by the manufacturer. In brief, 50 μlo fE D T A -
blood and 10 μl of Multitest reagent (BDIS) were added
to the dedicated TruCOUNT™ tubes (BDIS) containing
a fixed number of polystyrene reference beads and then
vortexed and left to incubate for 15 minutes at room
temperature. The Multitest reagent is combined with
four fluorescent [fluorescein isothiocyanate (FITC), phy-
coerythrin (PE), peridinin chlorophyll protein (PerCP),
and alophycocianin (APC)]-conjugated monoclonal anti-
bodies reagents for CD3/CD8/CD45/CD4 (FITC-CD3/
PE-CD8/PerCP-CD45/APC-CD4). Red blood cells were
then lysed by using FACS Lysing Solution (BDIS). The
lyse-no-wash stained samples were run on the FACSCa-
libur. Data were analyzed using MultiSet V2.2 software
(BDIS) for calculating the absolute and percentage
values of CD4 T cells. The CD8 T cell counting allowed
by the Multitest reagent was not used in the present
study
T h eA u t o 4 0a s s a yi sb a s e do nt h en ol y s ep r o c e d u r e
[20], which avoids the red blood cell lysis step, thereby
reducing assay variability due to changes in assay condi-
tions (time and temperature of incubation) as well as
differences in the susceptibility of cells to the lysis
reagents [21]. The Auto40 analyzer uses a volumetric
syringe moved by a stepper motor that draws and deli-
vers a known sample volume. Therefore, its absolute
volumetric counting allows the direct determination of
the number of cells per unit of sample volume without
the need for reference material such as micro beads
[8,22]. Thus, direct volumetric CD4 T cell measure-
ments were performed on the Auto40 using PE-conju-
gated anti-CD4 and PE-Dyomics649-conjugated anti-
CD45 monoclonal antibodies (Apogee Flow Systems
Ltd) for CD4 T cell count measurement. Anti-CD4 and
anti-CD45 monoclonal antibodies are resistant to high
temperatures because of their stabilization by a special
dehydration process under controlled conditions (pro-
prietary procedure, Bio-D) [11]. The Auto40 analytical
procedure avoids the need for a wash step. Briefly, 50 μl
of whole EDTA-blood was added into polypropylene
test tubes containing pre-dispensed, stabilized monoclo-
nal antibodies. After 25 minutes of incubation at room
temperature in the dark, 450 μl of phosphate buffered
saline were added. The no-lyse-no-wash stained samples
were run on the Auto40 flow cytometer, and CD4 T cell
count was obtained in absolute number and in percen-
tage. Analysis on the Auto40 flow cytometer is automa-
tically performed by the built-in very friendly software
“Auto-Lymphocyte” (Apogee Flow Systems Ltd), with
the possibility of controlling and assessing the quality of
the data analysis, particularly when the CD4 T cell num-
ber is less than 40 CD4 T cells/μl. Aside from simplify-
ing sample preparation, this system greatly facilitates
manipulations by lab technicians. The training of techni-
cians to use the Auto40 analyzer takes roughly one day.
Assessment of the precision of CD4 T cell counting in the
mobile unit
The precision of CD4 T cell counting on the Auto40
instrument in the mobile unit was assessed using 2 dif-
ferent blood samples. Intrarun (instrument) precision
was determined by preparing a large volume (10 ml) of
CD4-stained blood and repeating sample acquisition on
the instrument at least 10 times to determine the instru-
ment’s precision. Interrun precision, which includes the
variation induced by pipetting errors made by the tech-
nician (tube-to-tube variability), was assessed by repeat-
ing the entire CD4 staining procedure at least 10 times:
pipetting, sample preparation, staining, and sample
acquisition. By comparing the intrarun and interrun pre-
cision, a fairly good impression of instrument’sa n d
technician’s performance can be obtained. Interperson
variation (between different technicians) was not
assessed. Precision was expressed as the coefficient of
variance (CV) obtained by dividing the standard devia-
tion (SD) of all the measurements by the mean (CV% =
SD × 100/mean).
Statistical analyses
The Method Validator software, version 1.1.9.0. (Phi-
lippe Marquis, France) and the SAS-PC software (ver-
sion 8.2, SAS Institute, Cary, North Carolina, USA) were
used for analyses. Firstly, correlations between the abso-
lute CD4 T cell counts obtained by the reference FACS-
Calibur and the mobile Auto40 were established by the
Passing-Bablok method which, in common with all non-
parametric methods, is less sensitive to outliers [23].
Secondly, the agreement between the two methods was
illustrated by difference plots as proposed by Bland and
Altman [24,25]. The average difference between the 2
methods, referred to as bias, was marked on the graph
by a horizontal line, and the mean difference and the
limits of agreement with a 95% confidence interval (CI)
were also depicted.
To assess the clinical impact of using the Auto40
instead of the FACSCalibur in this setting, the sensitivity
and the specificity of the Auto40 was calculated to iden-
tify patients who had with the FACSCalibur a CD4 T
cell count below 200 cells/μl the threshold of immune-
restoration under ART and the threshold for therapeutic
initiation according to the 2006-revised WHO recom-
mendations [26] or 350 cells/μl, the new threshold for
ART initiation according to the 2010-revised WHO
guidelines [1]. For clinical significance of the
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Cohen’s k coefficient was calculated on the whole study
population [27].
Results
Accuracy of direct volumetric CD4 T cell measurements
on the Auto40 using EDTA-containing whole blood
Study volunteers were included irrespective of their HIV
sero-status (except children). The campaign in the sub-
urb of Yaoundé included 98 adults volunteers (median
age, 39.5 years; 28 males) for CD4 T cell count, and 93
children less than 5 years and more than 18 months (43
males). The campaign in Ambang Bikok included 69
adult volunteers (median age, 34 years; 39 males). Three
blood samples from adult volunteers showed poor pre-
analytical preparation when arriving at CIRCB, and were
excluded from further analysis. Finally, parallel CD4 T
cell measurements on both instruments, the Auto40 and
FACSCalibur, were available for a total of 257 tested
blood samples (Table 1).
In the suburb of Yaoundé, mean ± SD CD4 T cell
count was 996 ± 874 cells/μl (range, 5-4295) by Auto40,
and 989 ± 883 cells/μl (range, 5-4454) by FACSCalibur.
In Ambang Bikok, mean ± SD CD4 T cell count was
1041 ± 317 cells/μl (range, 236-1774) by Auto40, and
1032 ± 294 cells/μl (281-1616) by FACSCalibur. The dif-
ferences between Auto40 and FACSCAlibur were not
statistically significant in suburb of Yaoundé as in
Ambang Bikok (P > 0.5).
Results by Auto40 and FACSCalibur were highly corre-
lated using a non-parametric Passing-Bablok regression
analysis in Yaoundé (r
2 = 0.98, slope = 1.01, intercept =
8.1) (Figure 1, top) as in Ambang Bikok (r
2 = 0.92, slope =
1.07, intercept = -68) (Figure 1, bottom). The relation
between Auto40 and FACSCalibur did not differ from lin-
earity in suburb of Yaoundé as in Ambang Bikok (P > 0.1).
In the suburb of Yaoundé, the Auto40 results showed
a bias of +6.8 cells/μl (95% CI: -12.4 - 26.0) as compared
with FACSCalibur (Figure 1, top). In the village Ambang
Bikok, the Auto40 results showed a bias of +9.7 cells/μl
(95% CI: -19.9 - 39.4) as compared with FACSCalibur
(Figure 1, bottom). Thus, Bland-Altman analysis on the
relative differences between the absolute CD4 T cell
counts obtained with Auto40 and FACSCalibur with the
average absolute CD4 T cell counts results in suburb of
Yaoundé and Ambang Bikok showed a close agreement
between both methods. When pooling the 257 CD4 T
cell count measurements, the Auto40 yielded a mean
difference of +7.6 CD4 T cells/μl higher than by refer-
ence flow cytometry.
Analysis of CD4 T cell count measurement expressed
in percentage showed, similarly to CD4 T cell count
expressed in absolute numbers, a high correlation and a
close agreement between both CD4 T cell counting
methods in Yaoundé as in Ambang Bikok (data not
shown).
T h eF i g u r e2d e p i c t st h er e s u l t sf r o m9 3C D 4Tc e l l
count measurements from children aged less than 5
years and more than 18 months, expressed in absolute
number and in percentage. In this pediatric population,
analysis of CD4 T cell count measurement expressed in
percentage showed, similarly to CD4 T cell count
Table 1 CD4 T cell counting in Yaoundé suburb and Ambang Bikok village obtained by the Auto40 flow cytometer
installed in a therapeutic mobile unit, and by the FACSCalibur at the reference laboratory, expressed in 5
th-95
th
percentile and mean.
n* 5
th-9 5
th percentile Mean ± SD P value**
Yaoundé suburb 188
. Absolute CD4 T cells***
- Auto40 111-2624 996 ± 874
- FACSCalibur 110-2620 989 ± 883 NS
. Percent CD4 T cells
- Auto40 6.0-48.0 27.1 ± 13.6
- FACSCalibur 6.0-49.0 36.7 ± 13.1 NS
Ambang Bikok 69
. Absolute CD4 T cells
- Auto40 530-1585 1041 ± 317
- FACSCalibur 585-1511 1032 ± 294 NS
. Percent CD4 T cell
- Auto40 26.8-52.0 38.5 ± 7.9
- FACSCalibur 26.2-51.8 37.5 ± 8.0 NS
* Number of blood samples with successful CD4 T cells counting by both Auto40 and FACSCalibur;
** P value for comparison of mean ± SD by Auto40 versus FACSCalibur taken as reference;
*** Absolute CD4 T cells are expressed in cells/μl.
SD: Standard deviation; NS: Not significant
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Page 4 of 9expressed in absolute numbers, a high correlation and a
close agreement between both CD4 T cell counting
methods. Mean ± SD CD4 T cell count in percentage
was 32.7 ± 12.1%CD4 (range, 10-70) by Auto40, and
33.0 ± 12.8%CD4 (range, 9-75) by FACSCalibur. The
differences between Auto40 and FACSCAlibur were not
statistically significant (P > 0.5). Results by Auto40 and
FACSCalibur were highly correlated by regression analy-
sis (r
2 = 0.986, slope = 1.00, intercept = 0.0) (Figure 2,
C). The relation between Auto40 and FACSCalibur did
not differ from linearity (P > 0.5). The Auto40 results
showed a bias of -0.30%CD4+ (95% CI: -0.91 - 0.31) as
compared with FACSCalibur (Figure 2, C), thus demon-
strating a close agreement between both methods to
measure CD4 T cells in percentage.
Sensitivity and specificity to identify clinically-relevant
thresholds by the Auto40 installed in mobile unit
The sensitivity and specificity of primary CD4 T cell
counting on the Auto40 in mobile unit to identify
patients having less than (or more than) 200 CD4 T
cells/μl was evaluated on the 257 available CD4 T cell
count measurements. Taking into account a 10% bilat-
eral range (i.e., counts between 190 and 210 CD4 T
cells/μl were considered similar), the concordance
between the Auto40 and FACSCalibur methods was
high (k = 0.98; P < 0.01). The decision differed for 2
study individuals. Accordingly, the Auto40 had a sensi-
tivity of 87% and a specificity of 99% to identify indivi-
duals with CD4 T cell counts below 200 cells/μlw h e n
compared with the FACSCalibur results.
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Figure 1 Results from the campaigns in the suburb of Yaoundé (top) and in the village of Ambang Bikok (bottom), during which 188
and 69 CD4 T cell count measurements, respectively, were carried out in parallel by the Auto40 flow cytometer in mobile unit and
by FACSCalibur in the Centre International de Référence Chantal Biya, Yaoundé. - Left. Passing-Bablok agreement test between the CD4 T
cell count results expressed in cells/μl obtained with the Auto40 and FACSCalibur. The diagonal dotted line represents the idealline (no bias).
The full line represents the regression line of the distribution; - Right. Bland-Altman analysis on the relative differences between the absolute
CD4 T cell counts obtained with the Auto40 and FACSCalibur flow cytometers compared with the average absolute CD4 T cell count. The black
full line represents the mean relative difference, and the other broken lines represent the superior and inferior limits of agreement. The arrow
corresponds to the X abscise axis.
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Page 5 of 9The sensitivity and specificity of primary CD4 T cell
counting on the Auto40 in mobile unit to identify
patients having less than (or more than) 350 CD4 T
cells/μl was also evaluated on the 257 available CD4 T
cell count measurements. Considering a 10% bilateral
range (i.e., counts between 332 and 367 CD4 T cells/μl
were considered similar), the decision did not differ
between study according to both methods (k =0 . 9 6 ) .
The Auto40 had a sensitivity of 87% and a specificity of
98% to identify individuals with CD4 T cell counts
below 350 cells/μl when compared with the FACSCali-
bur results.
Precision of direct volumetric CD4 T cell measurements
on the Auto40 in mobile unit
The intra- and inter- run precisions were tested using 2
blood samples. The intrarun precision of Auto40 flow
cytometer, expressed as the coefficient of variance, was
3.7% for the first sample (mean ± SD: 425 ± 16 CD4 T
cells/μl) and 7.4% for the second sample (122 ± 9 CD4
Tc e l l s / μl), giving a mean intrarun precision of 5.5%.
The interrun precision performed on the same 2 sam-
ples was 6.1% (439 ± 27 CD4 T cells/μl) and 9.7% (133
± 13 CD4 T cells/μl), respectively, giving a mean interun
precision of the Auto40 in mobile unit of 7.9%.
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Figure 2 Results of 93 CD4 T cell count measurements from children aged less than 5 years and more than 18 months in the suburb
of Yaoundé, expressed in absolute number (cells/μl) and in percentage carried out in parallel by the Auto40 flow cytometer and by
FACSCalibur. -Aand C. Passing-Bablok agreement test between the CD4 T cell count results obtained with the Auto40 and FACSCalibur flow
cytometers, in absolute number (A) and in percentage (C). The diagonal dotted line represents the ideal line (no bias). The full line represents
the regression line of the distribution; -Band D. Bland-Altman analysis on the relative differences between the CD4 T cell counts obtained with
the Auto40 and FACSCalibur flow cytometers compared with the average CD4 T cell count, in absolute number (B) and in percentage (C). The
full line represents the mean relative difference, and the dotted lines represent the superior and inferior limits of agreement. The arrow
corresponds to the X abscise axis.
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In the present study, we demonstrated that CD4 T cell
counting can be integrated into a therapeutic mobile
unit and that the Auto40 flow cytometer, whether oper-
ated by a laboratory technician, performs acceptably
compared with the FACSCalibur for absolute as well
percentage count CD4 T cell testing. Thus, the essential
WHO recommended ART staging and monitoring diag-
nostic tests can be accurately conducted at therapeutic
mobile unit level using mini flow cytometer to accu-
rately count CD4 T cells. The Auto40 flow cytometer
installed in a mobile unit and operated far from its
reference laboratory gave a perfect correlation with the
reference method. The correlation was maintained over
all the dynamic range of values (5-4295 CD4 T cells/μl).
CD4 T cell counting in the therapeutic mobile unit per-
mitted identification of the majority of individuals with
CD4 T cells below 200 cells/μl, with a sensitivity of 87%
and a specificity of 99%, and all individuals with CD4 T
cells below 350 cells/μl, with a sensitivity of 87% and a
specificity of 98%, demonstrating the capacity of Auto40
in mobile unit to measure in clinical practice CD4 T
cells around the threshold of immune-restoration (200
cells/μl), and around the new threshold for therapeutic
initiation (350 cells/μl) according to the 2010-revised
WHO recommendations [1]. The procedure was fast,
and needed only 30 minutes to be completed, with a
capacity of 120 tests per day in routine. The technique
was found to be easy to carry out and highly reproduci-
ble, with intra- and inter- run precisions less than 10%,
considered as acceptable for clinical use [10]. Taken
together, our observations address the proof-of-concept
of point-of-care CD4 monitoring by therapeutic mobile
unit, and support the decentralization of ART in rural
settings with limited laboratory infrastructure. Indeed,
the sturdiness of the Auto40 system associated with the
use of heat-resistant reagents make possible the immu-
nological monitoring of HIV-infected adults and chil-
dren living in areas without laboratory facilities.
One of the main features of the Auto40 assay is the
use of stabilized monoclonal antibodies. The assay
reagents can be stored for prolonged period of time (up
to 12 months) at high temperature without any loss of
biological activity [11]. This feature is of potential appli-
cation to the screening of HIV-infected individuals in
resource-poor settings where conditions for the storage
of reagents, particularly during shipment and delivery,
cannot always be guaranteed. The thermo-stable mono-
clonal antibodies we used in the present study can be
kept as long as one year at room temperature, i.e.u pt o
+30°C, the stability at higher temperature being
unknown. The possibility of long-term storage of
reagents at room temperature should facilitate the plan-
ning of laboratory activities and reduce the costs related
to loss of reagents. Overall, the use of thermo-stable
reagents increases the accessibility to flow cytometry
testing, since the increase in manufacturing costs related
to the antibody stabilization procedure does not exceed
15% of the original cost [11].
The successful scale-up of ART will depend on the
ability to deliver health services closer to patients and
the community, in primary health care settings [28-30],
not only to reach more patients, but also to improve
patient outcomes, including higher retention rates [31]
and better virological suppression [32-36]. The UNAIDS
ART 2.0 model envisions decentralized ART that deli-
vers treatment and care easily and inexpensively, close
to where patients live [37]. Decentralization of diagnos-
tics, which are typically conducted at district or central
laboratories remote from primary health care settings, is
critical to this approach. Patients often make several
clinic visits to complete the testing process and results
may take days or weeks to return. As transport costs
and logistical challenges are significant causes of loss-to-
follow-up [38,39], tests conducted closer to the patient
may improve retention and treatment success.
A wide assortment of more cost-efficient and techni-
cally less complex analyzers using proven flow cytome-
try-based technology have been developed in response
to the overarching challenge of increasing access to CD4
T cell enumeration, and are especially suitable for
resource-constrained settings [40]. Affordable CD4 T
cell measurement, in absolute number and percentage,
has gradually been possible by using simple, compact
and robust low-cost new generation flow cytometers
operating as single-platform volumetric instruments
without the use of expensive micro beads [9]. Currently
available mini flow cytometers present convenient effi-
ciency when performed by well-trained laboratory tech-
nicians and when combined with good sample transport
systems [9,40]. In addition, several other point-of-care
CD4 testing options have been conceived, and some are
already on the market [41], all in a bid to improve
access to CD4 T cell monitoring, especially for rural
patients, and to reduce loss-to-follow-up of patients
[40,41].
The implementation of CD4 T cell counting in thera-
peutic mobile unit may help improve access to ART for
patients in need, especially for rural populations and
populations accessible mainly through mobile and out-
reach health services [15]. Previous experience on
mobile health units for expansion of antiretroviral treat-
ment to remote populations have been reported in Zam-
b i a[ 4 2 ] .T h em o b i l es e r v i c ei n c r e a s e dt h en u m b e ro f
ART clients in the study district probably because it
reduced the long distances required to travel to health
services in rural areas. Interestingly, clients found HIV-
infected in mobile unit were generally starting ART at
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Page 7 of 9an early stage of HIV disease [42], likely because mobile
ART services might have also encouraged people to
seek voluntary counseling and testing, much earlier
before presenting symptoms. Furthermore, involvement
of the community such as lay counselors and support
groups increased the number of patients retained at the
original site compared to hospitals [42]. Thus, in the
Zambian experience, transfers and lost-to-follow-up
patients at the mobile sites during the first six months
of ART were less frequent, with slightly higher retention
rates (70-76%) [42] than generally observed in African
hospital-based services (60%) [32]. Although HIV
screening in mobile unit was demonstrated to be highly
accepted in Cameroonese populations [15], the risk of
possible stigma should be always be prevented. Taken
together, mobile ART services in resource-limited set-
tings can increase the number of ART patients by redu-
cing the need to travel long distances to reach health
facilities, as well as enable patients to start ART at an
earlier stage in their disease when HIV diagnosis in
made in voluntary counseling and testing center.
Monitoring of CD4 T cell count is cost-effective and
may be cost-saving when compared to clinical monitor-
ing alone for determining the timing of ART initiation,
w a yb e f o r et h ed e v e l o p m e n tof life-threatening symp-
toms [43-45]. The issue of whether the monitoring of
patients on ART with a mobile unit is a valid economic
option remains unresolved. Mobile health clinics are an
appealing means of conducting outreach in that they
provide an appropriate setting for sexually transmitted
disease testing as well as HIV counseling, testing, and
referral services. Mobile health vans are expensive, how-
ever, frequently costing two to three times more per
patient compared with traditional clinics [46,47]. In
Uganda, the mobile clinic care for provision of ART has
shown to be less cost-effective than facility-based care
with higher incremental cost-effectiveness ratio, but
would be competitive in targeted “hard-to-reach” popu-
lation excluded from hospital-fixed health care [48].
Conclusions
The Auto40 flow cytometer installed in a therapeutic
mobile unit and operated far from its reference labora-
tory gave a perfect correlation with the reference
method, could be useful in carrying out immunological
monitoring of HIV-infected patients living in areas with-
out access to laboratory facilities, and could likely con-
tribute to the decentralization and scaling-up of ART in
Cameroon.
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